Characterizing metabolic changes in human colorectal cancer

Area of Science:

• Metabolomics and Cancer Research
• Biomarker Discovery for Colorectal Cancer (CRC)

Background:

• Colorectal cancer (CRC) is a leading cause of cancer death globally, emphasizing the need for improved early detection and diagnostic methods.
• Metabolomics offers a promising approach to understand cancer metabolism and identify diagnostic or prognostic biomarkers, but standardized methods are still evolving.

Purpose of the Study:

• To develop and validate a rapid metabolomic profiling method for distinguishing colorectal cancer (CRC) from non-neoplastic tissues.
• To identify specific metabolic alterations associated with different stages of CRC progression.
• To explore the potential of identified metabolites as diagnostic tools or therapeutic targets for CRC.

Main Methods:

• Utilized direct infusion traveling wave ion mobility mass spectrometry (IMMS) for rapid and efficient metabolomic analysis of colon tissue samples.
• Employed partial least squares discriminant analysis (PLS-DA) for statistical differentiation of metabolic profiles between sample groups.
• Identified key differentiating metabolites (m/z features) by cross-referencing with the human metabolome database.

Main Results:

• Successfully distinguished metabolic profiles of CRC tumors from matched non-neoplastic colonic epithelium.
• Identified distinct metabolic signatures differentiating primary tumors across various stages (T1-T4) and metastatic samples.
• Revealed significant alterations in fatty acid biosynthesis, oxidative, glycolytic, and polyamine pathways in CRC.

Conclusions:

• Colonic epithelial cells undergo significant metabolic reprogramming during CRC development.
• The identified distinct metabolites show potential as biomarkers for CRC diagnosis and risk stratification.
• These findings support the use of metabolomics for developing novel therapeutic strategies and primary prevention approaches for CRC.